Related Experiment Video
Updated: Jun 4, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
New insulins and insulin therapy
1Diabetes-Zentrum für Kinder and Jugendliche, Kinderkrankenhaus auf der Bult, Hannover, Germany. danne@hka.de
International Journal of Clinical Practice. Supplement
|February 18, 2011
Summary
New designer insulins, including ultra-fast and ultra-long acting types, offer improved diabetes management. Ongoing research is crucial to assess their safety and effectiveness, particularly regarding cancer risk.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetology
Background:
- The advent of 'designer' insulins (analogues) has advanced diabetes care.
- New ultra-fast-acting (Linjeta™) and ultra-long-acting (Degludec™) insulins are nearing clinical use.
- Safety concerns, especially regarding cancer risk, surround these novel insulin formulations.
Purpose of the Study:
- To review recent literature on new insulin preparations.
- To highlight contributions to ultra-fast and ultra-long-acting insulin analogue development.
- To examine potential side effects, with a focus on cancer risk.
Main Methods:
- Literature search of PubMed for "new insulins" published within the last year.
- Review of abstracts from major international diabetes meetings (ADA, EASD, ISPAD).
Main Results:
- Identified key articles contributing to the development of novel insulin analogues.
- Examined data on Linjeta™ (rapid-acting formulation) and Degludec™ (ultra-long-acting analogue).
- Found no conclusive evidence linking new insulins to increased cancer risk despite ongoing debate.
Conclusions:
- Further well-designed prospective studies are essential for evaluating the long-term effectiveness and safety of new insulins.
- Continuous monitoring is required to address safety concerns and optimize diabetes treatment regimens.
- The development of advanced insulin formulations continues to evolve, requiring rigorous scientific scrutiny.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...